MoonLake Immunotherapeutics (MLTX) Total Liabilities (2020 - 2026)

MoonLake Immunotherapeutics' Total Liabilities history runs 7 years deep, the most recent figure standing at $146.4 million for Q1 2026.

• In Q1 2026, Total Liabilities rose 48.31% year-over-year to $146.4 million; the TTM figure through Mar 2026 stood at $146.4 million (up 48.31% YoY), while the FY2025 annual figure was $120.0 million, up 388.76% from the prior year.
• Total Liabilities for Q1 2026 stood at $146.4 million, up from $120.0 million in the prior quarter.
• The five-year high for Total Liabilities was $206.8 million in Q1 2022, with the low at $3.9 million in Q2 2022.
• The 5-year median for Total Liabilities is $14.8 million (2024), against an average of $54.6 million.
• The sharpest annual moves came in 2022 and 2023: Total Liabilities jumped 4962.8% in 2022, then tumbled 96.28% in 2023.
• MoonLake Immunotherapeutics' Total Liabilities stood at $8.1 million in 2022, then surged by 61.57% to $13.0 million in 2023, then surged by 88.07% to $24.5 million in 2024, then surged by 388.76% to $120.0 million in 2025, then advanced by 22.01% to $146.4 million in 2026.
• Business Quant data shows MLTX's Total Liabilities at $146.4 million in Q1 2026, $120.0 million in Q4 2025, and $123.1 million in Q3 2025.